• Diagnosis of AIHA based on the presence of hemolytic anemia and serological evidence of anti-erythrocyte antibodies, detectable by the direct antiglobulin test.

• Participants who have disease progression after treatment with standard therapies that are known to confer clinical benefit, or who are intolerant to treatment, or who refuse standard treatment. There is no limit to the number of prior treatment regimens.

• Hemoglobin 7 to 10 g/dL.

• No evidence of a lymphoproliferative malignancy or other autoimmune-related underlying conditions.

• Eastern Cooperative Oncology Group performance status of 0 to 2.

• Willingness to avoid pregnancy or fathering children.